# A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)

> **NCT06814106** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 37 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Enlicitide Chloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06814106
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-06
- **Primary completion:** 2023-05-08
- **Final completion:** 2023-05-08
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06814106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06814106, "A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06814106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*